epirelop.blogg.se

In uncontrolled patients, there was a significant reduction in time above 250mg/dl (-5.8%) between 3 and 12 months follow-up. In patients controlled at baseline, there were significant reductions between 3 and 12 months in the percentage of time under 55mg/dl (-0.64%), above 250mg/dl (-1.8%) and glycemic variability (-2.6%). There was a significant reduction in severe hypoglycemic episodes, but only in the multiple imputation analysis. Patients with controlled HbA1c levels significantly worsened at 12 months (0.29%). This subgroup significantly improved their HbA1c levels at 3, 6 and 12 months (-0.46%, -0.44% and -0.35%, respectively). The mean age of patients was 12.6 years, with 56.4 percent had HbA1c values above 7.5 percent at baseline.